nobody has any excuse because they have amply been warned
nobody has any excuse because they have amply been warned openly by otc re this policy -they dont think any co should be below current and are using these policies and a political green light to force co's to upgrade to current
the co i was in didnt have any promo whatsoever anywhere near the time a ce was slapped - it had been 2 years since a promo- otc doesnt care-they force such co' s to upgrade to current -they are not allowed to return to no info or even limited info
OTC Markets Group's Policy Regarding Caveat Emptor
Caveat Emptor Logo
OTC Markets Group identifies securities with a Caveat Emptor symbol to inform investors that there may be reason to exercise additional care and perform thorough due diligence in making investment decisions for a particular security. The Caveat Emptor symbol is displayed in place of the OTCQX, OTCQB or OTC Pink marketplace designations and is distributed on market data feeds. The symbol is displayed wherever OTC Markets Group quote data is available. The designation is available to all market participants, including investors, broker-dealers, and clearing firms, so that they can make informed trading decisions.
Reasons Why a Caveat Emptor Designation is Assigned:
Promotion/Spam without Adequate Current Information — The security is being promoted to the public, but adequate current information about the company has not been made available to the public. Adequate current information must be publicly available during any period when a security is the subject of ongoing promotional activities. At such instances, as a matter of policy, when adequate current information is not made available, OTC Markets Group will label the security as "Caveat Emptor." Promotional activities may include spam email, unsolicited faxes or news releases, whether they are published by the company or a third party
Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Nvidia Invests $500 Million in Wayve Nvidia, known for its advanced AI technologies, is in discussions to invest a substantial $500 million into the U.K.-based autonomous driving startup Wayve. This move marks a significant step for Nvidia as it seeks to deepen its involvement in the rapidly evolving artificial intelligence sector. Strategic Importance of the Investment...
Continue Reading
Elevating Leadership at Vortex Companies Vortex Companies, known for its rapid growth in the trenchless infrastructure rehabilitation sector, has recently made significant leadership changes with the promotions of Jonathan Thomas and Connor Mathis. Thomas steps into the role of Senior Regional Vice President for the Coastal Region, while Mathis ascends to Regional Vice...
Continue Reading
Scilex Holding Company’s FDA Milestone with ELYXYB Scilex Holding Company, based in Palo Alto, California, has gained significant recognition with the U.S. FDA's acknowledgment of their Supplemental New Drug Application (SNDA) for ELYXYB. This marks a substantial step forward for the company, which is dedicated to creating and advancing non-opioid pain management...
Continue Reading
Advanced Proteins in the Spotlight Bio-Techne’s latest move is creating some serious buzz in the life sciences scene. They're not just talking the talk but walking the walk by expanding their R&D Systems AI-Engineered Designer Protein portfolio. What's the big news? They've engineered heat-stable and hyperactive proteins that promise to shake up fibroblast growth factor...
Continue Reading
Groundbreaking Advances in Surgical Infection Prevention PolyPid Ltd. has made headlines recently, unveiling remarkable topline results from their pivotal SHIELD II Phase 3 trial. This innovative study showcased D-PLEX100, a major breakthrough in preventing surgical site infections (SSIs), showing statistically significant reductions in both primary and secondary...
Continue Reading